|
Invited Speakers:
|
|
Dr John Andrews,Director of Regulatory Affairs, Americas, Chiltern International, United States of America Professor Lars Arendt-Nielsen,Founder and Director, Centre for Motor Interaction, Aalborg University, Denmark Dr Chantal Bélorgey,Head of Division on Evaluation of Special Status Medicinal Products and Clinical trials, Afssaps, France Nuala Brennan, Vice President Clinical Trials, PanGenetics BV, United Kingdom Dr John Davis, Senior Director, Group head - Research Clinical Pharmacology, Pfizer Global R&D, United Kingdom Frederique Delannois,Senior Principal Scientist, UCB Pharma SA, Belgium Dr. Bérengère Dumotier,Translational Sciences / Preclinical Safety, Novartis Institutes for BioMedical Research, Switzerland Dr Jeroen Elassaiss-Schaap,Modelling & Simulation Expert, Schering-Plough Research Institute, Netherlands Dr Paulo Fontoura,Translational Sciences / Preclinical Safety, Roche, Switzerland Dr Mitchell Friedman,Director of Toxicology, Takeda Global R&D, United States of America Dr Gary Gintant,Senior Group Leader, Chairman, Abbott QT Working Group, Abbott Laboratories, United States of America Professor, Dr Michel Goldman,Executive Director, Innovative Medicines Initiative, Belgium Baroness Susan Greenfield,CBE, Professor of Pharmacology, Oxford University, United Kingdom Dr Lars Grundemar,Associate Vice President, Experimental Medicine & Bioanalysis, Ferring Pharmaceuticals, Denmark Chris Harbron,Technical Lead Statistician, AstraZeneca, United Kingdom Dr Jackie Hunter,Senior Vice President, Science Environment Development, GlaxoSmithKline, United States Dr Orest Hurko,Assistant Vice President, Discovery Translational Research, Pfizer, Inc., United Kingdom Dr Mendel Jansen,Director, Modelling & Simulation, DAIICHI SANKYO DEVELOPMENT LTD., United Kingdom Dr Walter Janssens,Senior Preclinical Assessor, Pre-authorisation, Coordinator Early Phase Development, Federal Agency for Medicines and Health Products, Belgium Dr David Jones,Principal Scientific Officer, MHRA, United Kingdom Dr Lewis Kinter,Senior Director Safety Assessment, AstraZeneca, United States of America Dr Chetan Lathia,Director Global Clincal Pharmacology, Bayer Corp, United States Michèle Léonard,Senior Principal Scientist, UCB Pharma SA, Belgium Dr Dongzhou (Jeffery) Liu,Principal Clinical Investigator, Medical Affairs and Clinical Development, GlaxoSmithKline, United States Dr Johan Luthman,Vice President Neuroscience & Ophthalmology Research & Development, Franchise Integrator, Merck Ltd, United States Dr Roy Mansfield,Director, Safety and Risk Management, Pfizer, Inc., United Kingdom Dr Boaz Mendzelevski,Chief Medical Officer and Vice President Cardiology, Medifacts International Inc, United Kingdom Dr Alvaro Pereira,Clinical Research Advisor, Aepodia, Belgium Dr Yili Pritchett,Research Fellow, Director, Clinical Statistics, Global Stats & Data Mgmt, Abbott Laboratories, United States of America Dr Ignacio Rodriguez,Director Drug Safety Risk Management, Roche - Genentech, United States of America Dr Richard Sachse,Clinical Program Director, UCB Group, Schwarz BioSciences GmbH, Germany Dr Gareth Shackleton,Assistant Research Director, Global Metabolism and Pharmacokinetics, Sanofi-Aventis, United Kingdom Dr Magnus Sjogren,Head Translational Medicine, ECREM, Schering-Plough Research Institute, Netherlands Denis Smith,Academic Research Fellow, Pfizer, Inc., United Kingdom Dr Steffan Steffen,Medical Assessor, BfArM, Germany Dr Lloyd Stevens,Senior Research Fellow, Quotient Clinical, United Kingdom Jolanda van de Logt,Research Physician Phase IIa, Kendle Netherlands, Netherlands Dr Gabriel Vargas,Biomarker Expert, Roche, Switzerland» Dr Eckhard von Keutz,Senior Vice President, Head Global Early Development, Bayer Schering Pharma AG, Germany
|
|